Campuses:
What's Inside

HOT Home

University of Minnesota Physicians Clinic Appointment and Referral Information
  Home > Faculty > Robert Kratzke, MD
 

Robert Kratzke, MD

Associate ProfessorDOMHOT_Faculty_Kratzke09


Mailing Address:
Medicine – Hematology, Oncology and Transplantation Office
MMC 480 Mayo
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (612) 624-0123
Fax: (612) 625-6919
Email: kratz003@umn.edu
Preferred method of contact: email

Areas of Expertise

  • Lung Cancer
  • Melanoma
     

 

Biography
Dr. Kratzke graduated from the University of Washington School of Medicine in 1983 and completed his residency training in Internal Medicine at the University of Wisconsin Hospital and Clinics in 1986. Between 1986 and 1988, he did research at the McArdle Laboratory for Cancer Research at the University of Wisconsin Madison in the laboratory of Dr. Jeff Ross. He was a Medical Oncology Fellow at the National Cancer Institute (NCI) of the National Institutes of Health from 1988 to 1991, and stayed at the NCI doing research with Dr Frederick Kaye until 1994. From 1993 through 1994, Dr. Kratzke was also an Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. From 1994 to 2004, he was a Staff Physician at the Minneapolis VA Medical Center in the Section of Hematology/Oncology.
 
Research Interests
Dr. Kratzke’s research has centered around molecular abnormalities in lung cancer and mesothelioma, focusing primarily on cell cycle regulator genes and their loss of function in cancer. In addition, in collaboration with Dr. Michael Maddaus of the Section of General Thoracic Surgery, Dr. Kratzke is conducting research into the detection of micrometastatic disease in lung cancer and the acquired molecular abnormalities in micrometastases.
 
Selected Publications
Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, Kaye FJ. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. JNCI 1995, 87:1870-1875.

Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J. Rb and p16INK4 expression in resected non-small cell lung tumors. Cancer Res 1996, 56:3415-3420.

Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DT, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Research 1997, 57:1007-1011.

Frizelle SP, Grim J, Curiel DT, Geradts J, Kratzke RA. Re-expression of p16INK4 in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998, 16: 3087-3095.

Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA. Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Therapy 2000; 7:1421-1425.

Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 2001; 32:27-38.

Wong L,. Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002; 38:131-6.

Ho SB, Hyslop A, Albrecht R, Jacobson A, Spencer M, Rothenberger DA, Niehans GA, D'Cunha J, Kratzke RA. Quantification of colorectal cancer micrometastases in lymph nodes by nested and real-time reverse transcriptase-PCR analysis for carcinoembryonic antigen. Clin Cancer Res 2004; 10: 5777-5784.

Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004; 125: 1843-1852.

Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004; 64: 7479-7485.

Dudek AZ, Lesniewski-Kmak K, Bliss RL, Brunstein C, Condon DL, Kratzke RA. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung. 2005; 183:43-52.

Hoang CD, Guillaume TJ, Engel SC, Tawfic SH, Kratzke RA, Maddaus MA. Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs. Cancer Detect Prev. 2005; 29:509-17.

Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006; 66:352-61.

Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, Avdulov S, Mohorn RP, Whitson BA, Bitterman PB, Polunovsky VA, Kratzke RA. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 2006; 66:4256-62.

Sawhney MS, Kratzke RA, Lederle FA, Holmstrom AM, Nelson DB, Kelly RF. Endoscopic ultrasound and positron emission tomography for lung cancer staging. Clin Gastroenterol Hepatol. 2006; 4:846-51. PMID: 16682256

Sawhney MS, Kratzke RA, Lederle FA, Holmstrom AM, Nelson DB, Kelly RF. EUS-guided FNA for the diagnosis of advanced lung cancer. Gastrointest Endosc. 2006; 63:959-65.

Thumma SC, Kratzke RA. Translational control: a target for cancer therapy. Cancer Lett. 2007; 258:1-8.

Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA. Ras pathway activation in malignant mesothelioma. J Thorac Oncol. 2007 Sep;2(9):789-95.

Frizelle SP, Kratzke MG, Carreon RR, Engel SC, Youngquist L, Klein MA, Fourre L, Shekels LL, Kratzke RA. Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer Res. 2008; 28:1-7.

Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelsang NJ, Kindler HL, Kern JA, Cancer and Leukemia Group B. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008; 3:417-421.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008;26:848-855.

Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther. 2008 Nov;7(11):3586-97.

Whitson BA, D'Cunha J, Andrade RS, Kelly RF, Groth SS, Wu B, Miller JS, Kratzke RA, Maddaus MA. Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. Ann Thorac Surg. 2008 Dec;86(6):1735-44.

Whitson BA, D'Cunha J, Hoang CD, Wu B, Ikramuddin S, Buchwald H, Panoskaltsis-Mortari A, Kratzke RA, Miller JS, Maddaus MA. Minimally invasive versus open Roux-en-Y gastric bypass: effect on immune effector cells. Surg Obes Relat Dis. 2009 Mar-Apr;5(2):181-93.

Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW, Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 2009 May 5;100(9):1379-84.

Mathew J, Kratzke RA. Lung cancer and lung transplantation: a review. J Thorac Oncol. 2009 Jun;4(6):753-60. Review.

Jacobson BA, De A, Kratzke MG, Patel MR, Jay-Dixon J, Whitson BA, Sadiq AA, Bitterman PB, Polunovsky VA, Kratzke RA. Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer. 2009 Aug 4;101(3):424-31.

Dudek AZ, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. J Thorac Oncol. 2009 Aug;4(8):969-75.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer. 2009 Oct 6;101(7):1114-23.

Williams BW, Chang JJ, Chi RM, Marker PH, Frethem CD, Le CT, Kratzke RA, Kirstein MN. Cap-dependent translation blockade and fixed dose-rate gemcitabine: Interaction in an in vitro bioreactor system. Cancer Lett. 2009 Oct 18;284(1):37-46.

Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA. Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg. 2010 Jan;139(1):43-8.

Klein MA, Mayo KH, Kratzke RA. p16(INK4a) Peptide mimetics identified via virtual screening. Bioorg Med Chem Lett. 2010 Jan 1;20(1):403-5.

Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.  Anesth Analg. 2011 Dec;113(6):1353-64.

Patel MR, Sadiq AA, Jay-Dixon J, Jirakulaporn T, Jacobson BA, Farassati F, Bitterman PB, Kratzke RA.  Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.  Int J Oncol. 2012 Feb;40(2):577-82.

 

 

Notice of Privacy Practices


Return to: Department of Medicine: Medical School: Academic Health Center: U of M Home